<DOC>
	<DOCNO>NCT00038480</DOCNO>
	<brief_summary>The purpose study find drug lopinavir/ritonavir ( LPV/RTV ) safe well tolerate HIV infected infant . This study also determine effective dose LPV/RTV infant .</brief_summary>
	<brief_title>Safety Effectiveness Lopinavir/Ritonavir HIV Infected Infants</brief_title>
	<detailed_description>LPV/RTV show significant antiviral activity tolerability clinical trial adult child 6 month age . LPV/RTV approve FDA treat old child adult HIV . Data child 6 month , however , available . LPV/RTV approve infant less 6 month old , appropriate dose young infant know . Dosing guideline need young infant , early stage primary infection . This study help identify appropriate dose range LPV/RTV evaluate response therapy infant less 6 month age . The study also evaluate whether early therapy allow normal development immune system . Infants 14 day 6 month age receive LPV/RTV combination 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) choose physician . Twelve-hour pharmacokinetic sampling perform Day 14 drug treatment patient reach 12 month age . Patients undergo physical exam , medical history assessment , blood collection select study visit . Study visit occur every 2 week first 8 week , every 4 week end first year study . Study visit second year every 12 week end study . The parent guardian contact phone every 6 week monitor adverse drug effect . Participants age 6 week less 6 month old follow 96 week enrollment last participant . Participants age 14 week less 6 week follow 48 week enrollment last participant .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Inclusion Criteria HIV infect Viral load great 10,000 copies/ml within 30 day prior study entry Weigh 5.5 lb time enrollment Agree take 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) addition LPV/RTV Have consent parent guardian willing provide sign informed consent infant follow PACTG site Exclusion Criteria Currently take nonnucleoside reverse transcriptase inhibitor protease inhibitor ( PI ) study Previously use LPV/RTV . Patients treat previously PIs exclude . Prior concurrent maternal treatment LPV/RTV exclude . For patient le 6 week old time enrollment , less 34 week gestation delivery OR patient 6 week old time enrollment , less 32 week gestation delivery Any laboratory toxicity Grade 3 great . Hyperlipasemia Grade 2 high also exclude . Newly diagnose acute opportunistic serious bacterial infection require therapy time enrollment Chemotherapy active cancer Certain medication Any clinically significant condition , HIV infection , would interfere study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Lopinavir</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>